Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Strategies to Enhance the Therapeutic Efficacy, Applicability, and Safety of Genetically Engineered Immune Cells

Full text
Author(s):
Gomes de Lima, Sarah Caroline [1] ; Carvalho Fantacini, Daianne Maciely [1] ; Batista, Lais de Castro [1] ; Silveira, Roberta Maraninchi [1] ; Furtado, Izadora Peter [1] ; Rossetti, Rafaela [1] ; Brand, Heloisa [1] ; Covas, Dimas Tadeu [1] ; Botelho de Souza, Lucas Eduardo [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Ctr Cell Based Therapy, Hemotherapy Ctr Ribeirao Preto, Ribeirao Preto, SP - Brazil
Total Affiliations: 1
Document type: Journal article
Source: CRITICAL REVIEWS IN IMMUNOLOGY; v. 41, n. 1, SI, p. 41-67, 2021.
Web of Science Citations: 0
Abstract

The field of cell therapy is leading a paradigm shift in drug development. The recent convergence of several fields, including immunology, genetics, and synthetic biology, now allows for the introduction of artificial receptors and the design of entire genetic circuitries to finely program the behavior of injected cells. A prime example of these next-generation living drugs comes in the form of T cells expressing chimeric antigen receptors (CARs), which have already demonstrated definitive evidence of therapeutic efficacy against some hematological malignancies. However, several obstacles still restrict the antitumor efficacy of and impair the widespread use of CAR-T cells. Critical challenges include limited persistence and antitumor activity in vivo, antigen escape, scarcity of suitable single markers for targeting, and therapy-related toxicity. Nevertheless, intense research activity in this field has resulted in a plethora of creative solutions to address each of these limitations. In this review, we provide a comprehensive snapshot of the current strategies used to enhance the therapeutic efficacy, applicability, and safety of genetically engineered immune cells to treat cancer. (AU)

FAPESP's process: 20/02043-2 - Development of CRISPR/Cas9-based genome editing for the generation of allogeneic CAR-T cells
Grantee:Sarah Caroline Gomes de Lima
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 19/18702-8 - Generation and evaluation of antitumor efficiency of CAR-T cells harboring a T helper 17 phenotype
Grantee:Heloisa Brand
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 13/08135-2 - CTC - Center for Cell-Based Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC
FAPESP's process: 19/18672-1 - Evaluation of in vivo persistence of T lymphocytes expressing anti-CD19 chimeric antigen receptors
Grantee:Laís de Castro Batista
Support Opportunities: Scholarships in Brazil - Scientific Initiation